ArticleJournal of translational medicine2026
Mitochondrial dysfunction in the spinal cord contributes to peripheral hypersensitivity in a nitroglycerin-induced migraine model.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMitochondrial dysfunction was reported as a potential factor that contributes to the development of migraine and peripheral hypersensitivity. The recent accumulation of knowledge on mitochondrial involvement in migraine paved the way for a new non-pharmacological-therapeutic strategy like hyperbaric oxygen therapy (HBOT), which targets mitochondrial dysfunction. Yet, the efficacy of HBOT in modaulting migraine associated pain remains unclear.
methodsRats were injected with nitroglycerin (NTG, 10 mg/kg), a human migraine trigger, every other day for 9 days. Mechanical and thermal sensitivity, motor function, anxiety and depression-like behavior, and cognitive function were measured following chronic NTG treatment. The HBOT (2.5 ATA) was performed immediately after NTG injection and twice daily (12-hour intervals) for ten consecutive days. In order to assess mitochondrial function in the spinal cord (L1-L6), high-resolution respirometry was measured on day 12 using the OROBOROS-O2k. In addition, RT-PCR was performed at the end of the experiment to assess neuroinflammation and neuromodulation in the brain region involved in sensory and pain, including the trigeminal nucleus caudalis (TNC), hippocampus (HPC), somatosensory cortex (SSC), and amygdala (Amg).
resultsThe current result shows that chronic NTG treatment induces peripheral hypersensitivity (mechanical and thermal) without affecting motor and cognitive function. In addition, the NTG-treated group exhibits increased anxiety- and depression-like behaviors compared to the vehicle group. Furthermore, NTG treatment leads to changes in the expression of the pro-inflammatory cytokine marker (IL6), neuropeptides (CGRP) and neuronal activation marker (cFOS) in the brain region involved in pain processing (SSC, TNC, HPC, Amg). Moreover, mitochondrial dysfunction in terms of oxygen consumption was observed in the spinal cord (L1-L6) following chronic NTG treatment. In contrast, HBOT during NTG treatment attenuated the development of peripheral hypersensitivity and improved both neuroinflammation and mitochondrial function.
conclusionOur findings indicate that chronic treatment of the human migraine trigger (NTG) leads to peripheral hypersensitivity development, depression and anxiety-like behavior, these effects were reversed by HBOT, probably by alleviating neuroinflammation and mitochondrial function in the CNS. Taken together, the current findings underscore the fact that HBOT has anti-inflammatory and neuroprotective effects that modulate the development of NTG-induced peripheral hypersensitivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.